NASDAQ · NRXP
NRx Pharmaceuticals, Inc.
$2.26-$0.41 (-15.23%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.53% below the high.
Loading market information…
NASDAQ · DXR · USD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:22 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Daxor Corporation’s quoted price sits in the lower half of its reported 52-week range, 39.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Daxor Corporation’s forward annual dividend is $0.36 per share, paid monthly. The forward yield is 4.01% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Daxor Corporation’s next earnings report is currently expected on Mar 10, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Daxor Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:23 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2022 | Mar 2, 2023 | $0.81 | $96.40K-99.76% vs estimate |
|---|
KEEP COMPARING
$2.26-$0.41 (-15.23%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.53% below the high.
$2.49-$0.19 (-7.09%)
Adagene Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.66% below the high.
$2.17+$0.01 (+0.23%)
Great Elm Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.5% below the high.
$1.87-$0.07 (-3.61%)
XBiotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.64% below the high.
$1.13-$0.06 (-5.04%)
Gain Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.96% below the high.
$3.19-$0.08 (-2.45%)
Nephros, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.31% below the high.
$1.13-$0.04 (-3.42%)
Lite Strategy, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.7% below the high.
$3.40-$0.19 (-5.17%)
Adicet Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.77% below the high.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
